Medical Access in Colombia

Currently classified under Colombia's national narcotics framework for controlled psychotropic substances; the national sanitary regulator (INVIMA) has explicitly warned that psilocybin is not regulated or permitted in food products and has issued public alerts against commercial products claiming to contain psilocybin [1]INVIMA alert reported by Infobae. Possession or distribution of concentrated/synthetic psilocybin or unregistered psilocybin-containing products may be subject to criminal sanctions under Colombia's food and narcotics laws (see INVIMA communications and national resolution references cited by media coverage). Currently there is no national prescription/medical reimbursement program for psilocybin; authorized medical access would be limited to properly authorized clinical trials or research protocols approved by INVIMA/ethics committees.

Currently treated as an illegal/controlled substance for recreational use in Colombia and therefore not available as a reimbursed medical therapy in routine care. Interest and capacity to run clinical research exist (groups such as MAPS have engaged with Colombian researchers regarding MDMA‑assisted psychotherapy and there has been public/academic interest in MDMA studies for PTSD), meaning access is presently limited to authorized clinical trials and research programs rather than routine clinical prescribing [1]MAPS report [2]Country legal review. Outside of approved research there is no public insurance reimbursement or legal medical route for MDMA‑assisted therapy.

Esketamine (commercially known as Spravato) has been the subject of INVIMA review activity and appears in INVIMA meeting/acta documentation concerning medicinal product registration/assessment, indicating that the regulator is processing or has reviewed esketamine products for Colombia market considerations [1]INVIMA Acta No. 06 de 2025. In practice, esketamine, where present, is delivered under restricted, clinic‑based programs requiring supervised administration (mirroring international REMS/controlled‑use models) and is not a routine reimbursed outpatient prescription available through standard public formularies. Reimbursement and patient access depend on product registration status with INVIMA, commercial distribution agreements, and private insurer/IPS (institución prestadora de servicios de salud) policies; in the Colombian market such specialty, high‑cost psychiatric pharmaceuticals are typically introduced through private clinics or hospital outpatient programs with case‑by‑case coverage decisions rather than universal public coverage. Any claim of formal national public reimbursement should be verified against INVIMA registration status and EPS/insurer reimbursement decisions at the time of inquiry. [1]INVIMA Acta No. 06 de 2025 [2]International clinical review of esketamine (context).

Ketamine is an approved anesthetic and analgesic in Colombia and is used legally in medical settings (operating rooms, emergency medicine) under standard medical licensing and hospital formularies; additionally, off‑label use for psychiatric indications (e.g., treatment‑resistant depression, ketamine‑assisted psychotherapy) is performed in private clinics and hospital settings under physician supervision. Reimbursement for psychiatric/psychedelic uses of ketamine infusions is generally limited: racemic ketamine for anesthesia is included in standard hospital formularies and reimbursed as part of procedural care, but off‑label psychiatric infusion programs or private KAP (ketamine‑assisted psychotherapy) courses are commonly delivered by private providers and frequently paid out‑of‑pocket or via discretionary insurer approvals rather than standardized national reimbursement. Clinical and regulatory best practice in Colombia follows medical prescription and controlled‑substance handling rules; clinics offering infusion or intramuscular protocols operate under medical authorizations and local IPS registration requirements. For comparative/regulatory context, international reviews and Colombian practice summaries note that Spravato (esketamine) has a separate stricter delivery model while racemic ketamine remains an older, widely available hospital drug used off‑label in mental health contexts [1]Global ketamine/regulatory summary [2]Colombia ketamine context.

N,N‑DMT as an isolated/synthetic compound is treated as a controlled psychotropic substance in Colombia and its possession, distribution or sale outside authorized frameworks may trigger narcotics penalties; however, traditional plant preparations that contain DMT (notably ayahuasca/Yagé prepared from Banisteriopsis caapi and Psychotria viridis) are commonly practiced and have a protected status when used within indigenous ceremonial contexts — Colombian law and constitutional jurisprudence recognizes indigenous autonomy and traditional medicine practices, which has functionally permitted the ritual/ceremonial use of ayahuasca in many indigenous communities and spiritual practices [1]Ayahuasca legal/cultural protection overview [2]Relevant Colombian Constitutional jurisprudence on indigenous jurisdiction. For medical/reimbursement pathways, isolated DMT is not an approved reimbursed therapy in routine public health programs; clinical access is limited to authorized research protocols or protected indigenous ritual contexts.

5‑MeO‑DMT (synthetic or concentrated preparations) is treated as a controlled psychotropic substance in most legal frameworks and is not an authorized reimbursable medicine in Colombia; organized use occurs in private retreats or informal ceremonial contexts in some regions, but legal status means there is no formal medical program or reimbursement for 5‑MeO‑DMT and authorized access is restricted to properly approved clinical research. Guidance in regional practice and reporting highlights safety and conservation concerns around natural sources (e.g., Bufo alvarius secretion) and the lack of national regulatory authorization for therapeutic use outside research. For safety/clinical interest reporting see regional legal surveys and practice overviews. [1]DMT/5‑MeO‑DMT legal overview [2]Regional risk reporting.

Ibogaine occupies a legal grey zone in many Latin American jurisdictions and Colombia has been a destination for ibogaine clinics catering to international medical tourism; such use is typically provided through private clinics and is not part of standardized public reimbursement programs. Because ibogaine is not a routinely registered, reimbursed medication for addiction treatment in Colombia, access is by private payment under clinic‑specific protocols; safety monitoring, cardiac screening, and informed consent are critical due to known cardiotoxicity risks. Global coverage and reporting on ibogaine note Colombia as one of several countries where private clinics operate, but formal governmental approval or public reimbursement of ibogaine therapy is not established. [1]Global ibogaine status and medical‑tourism reporting.

Ayahuasca (Yagé) as a traditional plant medicine prepared from Banisteriopsis caapi and Psychotria viridis is broadly tolerated and used in Colombia within indigenous and syncretic spiritual contexts; the Colombian legal framework and constitutional jurisprudence that recognizes indigenous autonomy and traditional practices has functionally protected ceremonial ayahuasca use and the cultural practice of Yagé in many indigenous communities. Importantly, this protection generally applies to traditional/ceremonial contexts and does not equate to commercialized, mass‑market therapeutic distribution through regulated medical reimbursement channels. Isolated DMT (the active molecule) remains controlled when presented as a synthetic, concentrated product outside of recognized traditional contexts. For cultural/ legal context see indigenous‑rights jurisprudence and summaries of plant medicine regulation in Colombia. [1]Ayahuasca legal/cultural protection summary [2]Colombian Constitutional jurisprudence on indigenous jurisdiction.

Mescaline as an isolated synthetic alkaloid is treated as a controlled psychotropic substance and is not an authorized reimbursable medical therapy in Colombia. As with other jurisdictions, some cacti that naturally contain mescaline (e.g., certain Echinopsis species) occupy a more ambiguous legal position in practice, but extracted or concentrated mescaline is legally controlled and not permitted for medical reimbursement outside properly authorized research or exceptional, indigenous‑religious permissions where applicable. Access for therapeutic use would be limited to clinical trials or tightly regulated research protocols. (General regional legal summaries and country legal reviews support this classification.) [1]Country legal review on mescaline [2]Comparative status of mescaline/cacti.

Currently classified as a strictly controlled substance under Colombia's national drug scheduling and narcotics enforcement laws with no authorized medical use outside of approved clinical research. Synthetic substituted phenethylamines of the 2C family (2C‑B, 2C‑E, etc.) are treated as illegal/controlled compounds and are not part of reimbursed medical care or licensed therapeutic programs in Colombia. Access is limited to authorized scientific research where permitted by INVIMA and ethics committees.